Biochemical and Molecular Pharmacology in Drug Discovery comprises fundamental biochemical and molecular aspects of drug discovery and basic understanding of modern drug discovery approaches, along with certain key topics related to molecular pharmacology of drugs and therapeutics. The book explains the phenomena of drug-target interactions, considering different biochemical systems and cellular strategies. With the advent of technologies, current advances, and research trends move toward molecular and/or target-based drug design and discovery. Through this book, readers will gain skills and knowledge with a thorough understanding of the subject of biochemical and molecular pharmacology in a comprehensive and systematic manner. Molecular pharmacology has gained significant momentum among researchers, scientists, and academicians because of its increasing interest in drug discovery research across the globe. Molecular pharmacology involves a fundamental understanding of drug actions at the molecular level with the help of several tools and techniques of biochemical and molecular biology.
Table of Contents
Section-A: Biochemical Aspects1. Biochemical, Biophysical and Molecular Biology Techniques
2. Structure and Functions of Biomolecules
3. Transcription Factors and Gene Expression
4. Receptors and Signal Transduction
5. Pharmacokinetics and Pharmacodynamics
Section B: Molecular Aspect
6. Overview of Drugs and Drug Targets
7. Proteins as Drug Targets
8. Nucleic Acids as Drug Targets
9. Molecular Cloning of Drug Targets
10. Pharmacogenomics
11. Drug-Receptor Interactions
Section C: Drug Design and Discovery
12. Fundamental Approaches of Drug Discovery
13. Design of Enzyme Inhibitors
14. Drug Metabolism, Prodrugs and Drug Discovery
15. Reverse Pharmacology and Drug Repositioning in Drug Discovery
16. Bioinformatics and CADD Approaches in Drug Discovery
17. Artificial Intelligence-based protein structure prediction and systems biology-guided smart drug screening
Section D: Key Aspects of Molecular Pharmacology
18. Recombinant DNA Technology and Gene Therapy
19. Molecular Neuropharmacology and Neurotherapeutics
20. Molecular Oncobiology and Cancer Chemotherapeutics
21. Molecular Inflammopharmacology and Therapeutics
22. Molecular Immunopharmacology and Immunotherapeutics
23. Molecular Pharmacology of Nitric oxide and Therapeutics
24. Molecular Cardiopharmacology and Therapeutics
25. Molecular Endocrine Pharmacology and Therapeutics
26. Molecular Viral Infections and Anti-viral Therapeutics
27. Molecular Bacterial Infections and Anti-bacterial Therapeutics Conclusion
Authors
William Chi Shing Cho Queen Elizabeth Hospital, Hong Kong, China. William C.S. Cho, PhD, RCMP, FHKIMLS, FHKSMDS, Chartered Scientist (UK), FIBMS (UK). Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China. Dr. Cho's primary research interests focus on cancer research to discover biomarkers for cancer diagnosis, treatment prediction, and prognosis. As a seasoned researcher, Dr. Cho has conducted cancer research using molecular biology, proteomics, genomics, immunology, bioinformatics, and next-generation sequencing technologies. Dr. Cho has published more than 600 peer-reviewed papers (Lancet, Lancet Oncology, Annals of Oncology, Lancet Gastroenterology & Hepatology, Advanced Science, Nature Communications, PNAS, Molecular Cancer, Journal of Thoracic Oncology, Journal of the National Cancer Institute, Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Theranostics, etc.) covering cancer biomarkers, proteomics, noncoding RNA, traditional Chinese medicine, and dozens of books (including An Omics Perspective on Cancer Research, MicroRNAs in Cancer Translational Research, Drug Repurposing in Cancer Therapy: Approaches and Applications, Supportive Cancer Care with Chinese Medicine, etc.). The cumulative impact factor of journals exceeds 4500, and the papers have been cited >25,000 times. Dr. Cho is listed among the top 2% of the most influential scientists in the world. In addition, Dr. Cho has served as a research grant reviewer for many international research funds, including the Hope Funds for Cancer Research (United States), Cancer Research (United Kingdom), National Medical Research Council (Singapore), etc. Chukwuebuka Egbuna Chartered Chemist and Academic Researcher, Nigeria.Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
Mithun Rudrapal Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research, India. Mithun Rudrapal is an Associate Professor and Head at the Department of Pharmaceutical Chemistry, Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research, Pune, India. Dr. Rudrapal has been actively engaged in teaching and research in the field of Pharmaceutical and Allied Sciences for more than 12 years. He has over 100 publications in peer-reviewed international journals to his credit and has filed a number of Indian patents. In addition, Dr. Rudrapal is the author or editor over a dozen published or forthcoming books or book chapters. Dr. Rudrapal works in the area of Medicinal Chemistry, CADD, Pharmacology, Drug Repurposing, Phytochemistry, Herbal Drugs and Nanophytotherapeutics. His research interests include discovery and development of drugs for infectious diseases, diabetes and inflammatory disorders from synthetic as well as plant sources.
